

# Alexion Pharmaceuticals Incorporated

[View the current Alexion Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/346-Alexion+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/346-Alexion+Pharmaceuticals+Incorporated.html>)

## Contact Details:

352 Knotter Drive  
Cheshire

Tel: 203 272 2596

Fax: 203 772 3655

Email: [alexion.europe@alxn.com](mailto:alexion.europe@alxn.com)

06410

United States of America

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.

Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor approved in the United States, European Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.

## Recent Publications by Alexion Pharmaceuticals Incorporated:



- [Importance of technical operations: lessons from evolving biotherapeutics production methods.](#)  
*Research and development connect technology and innovation to product...* 22nd September, 2009  
Fermentation and Cell Culture Development, Technical Operations, Alexion- Trends Biotechnol. 2009 Nov;27(11):612-4. Epub 2009 Sep 16. ([DOI Direct Link](#))
- [Kinetic analysis of a monoclonal therapeutic antibody and its single-chain homolog by surface plasmon resonance.](#)  
*Monoclonal antibodies (mAbs) and antibody fragments have become an...* 2nd September, 2009  
Alexion Pharmaceuticals, Cheshire, CT 06410, USA.- Anal Biochem. 2009 Aug 29. ([DOI Direct Link](#))
- [C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients.](#)  
*We explored whether a functionally blocking anti-C5 monoclonal antibody...* 4th July, 2008  
Alexion Pharmaceuticals, Inc., Cheshire, CT, USA.- Am J Transplant. 2008 Jun;8(6):1129-42. Epub

- 2008 Apr 29. ([DOI Direct Link](#))
- [Characterization of cartilage from H-transferase transgenic pigs.](#)  
*Cartilage engineering is the object of intense research as a result of...* 25th June, 2008  
 Department of Molecular Sciences, Alexion Pharmaceuticals, Inc, Cheshire,- *Transplant Proc.* 2008 Mar;40(2):554-6. ([DOI Direct Link](#))
  - [Mass spectrometry and HPLC with fluorescent detection-based orthogonal approaches to characterize N-linked oligosaccharides of recombinant monoclonal antibodies.](#)  
*A number of HPLC and mass spectrometric techniques are used to...* 5th June, 2008  
 Alexion Pharmaceuticals, Cheshire, CT, USA.- *Methods Mol Biol.* 2008;446:347-61. ([DOI Direct Link](#))
  - [Comparability and monitoring immunogenic N-linked oligosaccharides from recombinant monoclonal antibodies from two different cell lines using HPLC with fluorescence detection and mass spectrometry.](#)  
*One of the most important structural features of recombinant monoclonal...* 5th June, 2008  
 Alexion Pharmaceuticals, Cheshire, CT, USA.- *Methods Mol Biol.* 2008;446:333-46. ([DOI Direct Link](#))
  - [Monitoring glycosylation of therapeutic glycoproteins for consistency by HPLC using highly fluorescent anthranilic acid \(AA\) tag.](#)  
*Majority of protein drugs in development today are glycoproteins e.g...* 5th June, 2008  
 Alexion Pharmaceuticals, Cheshire, CT, USA.- *Methods Mol Biol.* 2008;446:317-31. ([DOI Direct Link](#))
  - [Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.](#)  
*The complement system provides critical immunoprotective and...* 29th February, 2008  
 Alexion Pharmaceuticals, Inc., 352 Knotter Drive, Cheshire, Connecticut- *Nat Biotechnol.* 2007 Nov;25(11):1256-64. ([DOI Direct Link](#))
  - [Characterization of porcine tumor necrosis factor receptor 2: implications for xenotransplantation.](#)  
*Clinical solid organ xenotransplantation is precluded by the strong immune...* 14th November, 2007  
 Department of Molecular Sciences, Alexion Pharmaceuticals Inc, Cheshire,- *Transplant Proc.* 2007 Sep;39(7):2443-6. ([DOI Direct Link](#))
  - [Role of complement component C5 in cerebral ischemia/reperfusion injury.](#)  
*We evaluated the role of complement component C5 during the course of...* 19th September, 2006  
 Department of Preclinical Sciences, Alexion Pharmaceuticals Inc.,- *Brain Res.* 2006 Jul 19;1100(1):142-51. Epub 2006 Jun 15. ([DOI Direct Link](#))
  - [Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response.](#)  
*The role of complement component C5 in asthma remains controversial. Here...* 12th August, 2005  
 Alexion Pharmaceuticals Inc., Cheshire, Connecticut 06410, USA.- *J Clin Invest.* 2005 Jun;115(6):1590-600. Epub 2005 May 12. ([DOI Direct Link](#))
  - [The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.](#)  
*CONTEXT: The efficient sequestration of hemoglobin by the red blood cell...* 12th April, 2005  
 Alexion Pharmaceuticals,- *JAMA.* 2005 Apr 6;293(13):1653-62. ([DOI Direct Link](#))
  - [Use of porcine tumor necrosis factor receptor 1-Ig fusion protein to prolong xenograft survival.](#)  
*BACKGROUND: Delayed rejection of xenografts is a major hurdle that needs...* 5th March, 2005  
 Department of Molecular and Preclinical Sciences, Alexion Pharmaceuticals- *Xenotransplantation.* 2004 Nov;11(6):491-502. ([DOI Direct Link](#))
  - [Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.](#)  
*The importance of the complement system in the pathophysiology of systemic...* 14th January, 2005  
 Alexion Pharmaceuticals Inc., Cheshire, CT 06410, USA.- *Lupus.* 2004;13(5):328-34.
  - [CD86 blockade in genetically modified porcine cells delays xenograft rejection by inhibiting T-cell and NK-cell activation.](#)  
*Porcine xenografts transplanted into primates are rejected in spite of...* 6th October, 2004  
 Department of Molecular Science, Alexion Pharmaceuticals Inc., 352 Knotter- *Cell Transplant.* 2004;13(1):75-87.

**Press Releases on Alexion Pharmaceuticals Incorporated:**

<a href="#">Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference</a>	23rd November, 2009	Accuray Incorporated	SUNNYVALE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at
<a href="#">Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter</a>	23rd November, 2009	Transcept Pharmaceuticals, Inc.	POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA)
<a href="#">NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options</a>	23rd November, 2009	National Comprehensive Cancer Network	Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy
<a href="#">Poniard Announces \$7.4 Million Financing</a>	23rd November, 2009	Poniard Pharmaceuticals	SAN FRANCISCO, Nov. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals (Nasdaq: PARD) today announced the sale of 3,465,878 of its common shares to Azimuth Opportunity Ltd. for gross proceeds of
<a href="#">Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman</a>	23rd November, 2009	Ligon Discovery, Inc.	CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment

**BioNews Results for Alexion Pharmaceuticals Incorporated**



- [Alexion Pharmaceuticals to Present Soliris Data at Annual ASH Meeting](#)

- Individual.com: Nov 13 2009 6:52AM Matching: alexion pharmaceuticals*
- [Alexion Pharmaceuticals to Present Soliris Data at Annual ASH Meeting](#)  
*TradingMarkets: Nov 13 2009 5:28AM Matching: alexion pharmaceuticals*
  - [Alexion Pharmaceuticals To Present At Credit Suisse's 2009 Healthcare Conference: Webcast At 10:00 AM ET](#)  
*RTTNews.com: Nov 12 2009 2:49PM Matching: alexion pharmaceuticals*
  - [News and FDA Updates for Alexion \(Nasdaq:ALXN\), Biogen \(NASDAQ:BIIB\), Elan \(NYSE:ELN\)](#)  
*Los Angeles Chronicle: Nov 12 2009 9:58AM Matching: alexion pharmaceuticals*
  - [News and FDA Updates for Alexion \(Nasdaq:ALXN\), Biogen \(NASDAQ:BIIB\), Elan \(NYSE:ELN\)](#)  
*American Chronicle: Nov 12 2009 7:53AM Matching: alexion pharmaceuticals*
  - [Researchers To Present Additional Data On Soliris\(R\) \(eculizumab\) For The Treatment Of Patients With PNH At Th](#)  
*Medical News Today: Nov 12 2009 6:19AM Matching: alexion pharmaceuticals*
  - [Researchers to Present Additional Data on Soliris \(eculizumab\) for the Treatment of Patients With PNH at the A](#)  
*Pharma Live: Nov 12 2009 12:03AM Matching: alexion pharmaceuticals*
  - [Researchers to Present Additional Data on Soliris \(eculizumab\) for the Treatment of Patients With PNH at the](#)  
*Freshnews.com: Nov 11 2009 1:49AM Matching: alexion pharmaceuticals*
  - [Alexion Pharmaceuticals Inc. \(ALXN\) to Present at Lazard Capital Markets 6th Annual Healthcare Conference](#)  
*BioSpace: Nov 11 2009 7:42PM Matching: alexion pharmaceuticals*
  - [Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference](#)  
*Pharma Live: Nov 11 2009 6:37PM Matching: alexion pharmaceuticals*
  - [Alexion Pharmaceuticals Inc. \(ALXN\) Release: Researchers to Present Additional Data on Soliris\(R\) \(eculizumab\)](#)  
*BioSpace: Nov 11 2009 7:45PM Matching: alexion pharmaceuticals*
  - [Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference](#)  
*Individual.com: Nov 11 2009 4:27PM Matching: alexion pharmaceuticals*
  - [Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference](#)  
*Yahoo! Canada: Nov 11 2009 3:55PM Matching: alexion pharmaceuticals*
  - [Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting](#)  
*News-Medical.Net: Nov 11 2009 5:54AM Matching: alexion pharmaceuticals*
  - [Researchers to Present Additional Data on Soliris \(eculizumab\) for the Treatment of Patients With PNH at the A](#)  
*NewsBlaze: Nov 11 2009 12:13AM Matching: alexion pharmaceuticals*

#### Alexion Pharmaceuticals Incorporated Clinical Trials:



- [Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria \(PNH\) Patients Treated With Eculizumab](#)





## Alexion Pharmaceuticals Incorporated Patents:

- 7598353- [Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof](#)
- 6803230- [Phagemid vectors](#)
- 6498285- [Methods for producing transgenic pigs by microinjecting a blastomere](#)
- 6355245- [C5-specific antibodies for the treatment of inflammatory diseases](#)
- 6338820- [Apparatus for performing assays at reaction sites](#)
- 6074642- [Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis](#)
- 6040428- [Porcine E-selectin](#)
- 5891645- [Porcine E-selectin](#)
- 5871997- [Methods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha \(1,3\) galactosyl epitopes](#)
- 5853722- [Use of C5-specific antibodies for reducing immune and hemostatic dysfunctions during extracorporeal circulation](#)
- 5847082- [Terminal complement inhibitor fusion proteins](#)
- 5643770- [Retroviral vector particles expressing complement inhibitor activity](#)
- 5627264- [Chimeric complement inhibitor proteins](#)
- 5624837- [Nucleic acid encoding chimeric complement inhibitor proteins](#)
- 5580766- [Retroviral vector particles for transducing non-proliferating cells](#)
- 5576201- [Retroviral vector particles for transducing non-proliferating cells](#)
- 6919189- [Nested oligonucleotides containing a hairpin for nucleic acid amplification](#)
- 6982323- [Chimeric proteins for diagnosis and treatment of diabetes](#)
- 7598030- [Antibodies against cancer produced using masked cancer cells as immunogen](#)
- 7482435- [Rationally designed antibodies](#)
- 7435412- [Chronic lymphocytic leukemia cell line](#)
- 7427665- [Chronic lymphocytic leukemia cell line](#)
- 7414111- [Engineered templates and their use in single primer amplification](#)
- 7408041- [Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof](#)
- 7405279- [Chimeric proteins for diagnosis and treatment of diabetes](#)
- 7399594- [Hybrid antibodies](#)
- 7396917- [Rationally designed antibodies](#)
- 7393648- [Hybrid antibodies](#)
- 7384915- [Chimeric insulin-gad proteins for treating patients with type 1 diabetes or at risk of developing type 1 diabetes](#)
- 7361339- [Methods for reducing mortality associated with acute myocardial infarction](#)
- 7306906- [Engineered templates and their use in single primer amplification](#)
- 7279158- [Methods for the treatment of inflammatory joint disease](#)
- 7041503- [Modified myelin basic protein molecules](#)
- 5562904- [Retroviral transduction of cells using soluble complement inhibitors](#)

**BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

